Impact of fetal growth restriction on pregnancy outcome in women undergoing expectant management for preterm pre‐eclampsia

Author:

Cluver C. A.123ORCID,Bergman L.14,Bergkvist J.4,Imberg H.56ORCID,Geerts L.1ORCID,Hall D. R.1,Mol B. W.78ORCID,Tong S.23,Walker S. P.23

Affiliation:

1. Department of Obstetrics and Gynaecology Stellenbosch University and Tygerberg Hospital Cape Town South Africa

2. Mercy Perinatal Mercy Hospital for Women Melbourne VI Australia

3. Translational Obstetrics Group University of Melbourne Melbourne VI Australia

4. Department of Obstetrics and Gynecology Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg Gothenburg Sweden

5. Statistiska Konsultgruppen Gothenburg Sweden

6. Department of Mathematical Sciences Chalmers University of Technology and University of Gothenburg Gothenburg Sweden

7. Department of Obstetrics and Gynaecology, Monash School of Medicine Monash University Melbourne VI Australia

8. Aberdeen Centre for Women's Health Research, Institute of Applied Health Sciences, School of Medicine, Medical Sciences and Nutrition University of Aberdeen Aberdeen UK

Abstract

ABSTRACTObjectivesTo assess whether coexisting fetal growth restriction (FGR) influences pregnancy latency among women with preterm pre‐eclampsia undergoing expectant management. Secondary outcomes assessed were indication for delivery, mode of delivery and rate of serious adverse maternal and perinatal outcomes.MethodsWe conducted a secondary analysis of the Pre‐eclampsia Intervention (PIE) and the Pre‐eclampsia Intervention 2 (PI2) trial data. These randomized controlled trials evaluated whether esomeprazole and metformin could prolong gestation of women diagnosed with pre‐eclampsia between 26 and 32 weeks of gestation undergoing expectant management. Delivery indications were deteriorating maternal or fetal status, or reaching 34 weeks' gestation. FGR (defined by Delphi consensus) at the time of pre‐eclampsia diagnosis was examined as a predictor of outcome. Only placebo data from PI2 were included, as the trial showed that metformin use was associated with prolonged gestation. All outcome data were collected prospectively from diagnosis of pre‐eclampsia to 6 weeks after the expected due date.ResultsOf the 202 women included, 92 (45.5%) had FGR at the time of pre‐eclampsia diagnosis. Median pregnancy latency was 6.8 days in the FGR group and 15.3 days in the control group (difference 8.5 days; adjusted 0.49‐fold change (95% CI, 0.33–0.74); P < 0.001). FGR pregnancies were less likely to reach 34 weeks' gestation (12.0% vs 30.9%; adjusted relative risk (aRR), 0.44 (95% CI, 0.23–0.83)) and more likely to be delivered for suspected fetal compromise (64.1% vs 36.4%; aRR, 1.84 (95% CI, 1.36–2.47)). More women with FGR underwent a prelabor emergency Cesarean section (66.3% vs 43.6%; aRR, 1.56 (95% CI, 1.20–2.03)) and were less likely to have a successful induction of labor (4.3% vs 14.5%; aRR, 0.32 (95% CI, 0.10–1.00)), compared to those without FGR. The rate of maternal complications did not differ significantly between the two groups. FGR was associated with a higher rate of infant death (14.1% vs 4.5%; aRR, 3.26 (95% CI, 1.08–9.81)) and need for intubation and mechanical ventilation (15.2% vs 5.5%; aRR, 2.97 (95% CI, 1.11–7.90)).ConclusionFGR is commonly present in women with early preterm pre‐eclampsia and outcome is poorer. FGR is associated with shorter pregnancy latency, more emergency Cesarean deliveries, fewer successful inductions and increased rates of neonatal morbidity and mortality. © 2023 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.

Funder

Preeclampsia Foundation

Svenska Läkaresällskapet

Norman Beischer Medical Research Foundation

Publisher

Wiley

Subject

Obstetrics and Gynecology,Radiology, Nuclear Medicine and imaging,Reproductive Medicine,General Medicine,Radiological and Ultrasound Technology

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3